Cresilon Highlights TRAUMAGEL at the Military Health Symposium
Cresilon Inc. is proud to announce that it will be presenting an exciting case study on its innovative hemostatic medical device, TRAUMAGEL, at an upcoming significant military health gathering. The case study focuses on the practical application of TRAUMAGEL in emergency trauma situations and showcases how this advanced device addresses critical needs in bleeding control.
Poster Presentation Details
The presentation is set to take place during the Military Health System Research Symposium (MHSRS), which focuses on military-unique health issues. The details about Cresilon's participation in this notable event are as follows:
- Poster Title: A Case Study Demonstrating the Utility of TRAUMAGEL in Emergency Hemorrhagic Trauma Setting
- Abstract ID: MHSRS-25-15025
- Presenter: Dr. Dhanushka Vitharana, M.D., associated with a leading health science center
- Session Topic: Hemorrhage Control and Vascular Dysfunction
- Date and Time: The presentation is scheduled for Tuesday, during the early evening hours
- Location: Gaylord Palms Resort and Convention Center
Cresilon representatives will be available for discussions regarding the immediate deployment of TRAUMAGEL for rapid bleeding control across various emergency response and military situations. Attendees are encouraged to visit Booth #1013 for insights and interactions regarding this groundbreaking technology.
The Importance of MHSRS
The MHSRS stands as the premier scientific meeting organized by the Department of Defense, serving as a platform for sharing cutting-edge research and advancements pertinent to military health care. This unique gathering provides invaluable opportunities for military health professionals, researchers, and industry experts to exchange knowledge and foster collaborations that directly impact the well-being of service members and their families.
Innovative Technology with a Mission
Cresilon is not just a name in biotechnology; it represents a revolution in hemostatic solutions. By harnessing proprietary hydrogel technology, Cresilon has developed devices that effectively stop bleeding in mere seconds. This plant-based advancement stands as a testament to the potential of modern science in trauma care.
The company's focus remains not only on improving medical outcomes but also on addressing the specific requirements of trauma care, biosurgery, and even animal health. With a mission centered around saving lives, Cresilon's innovations have garnered recognition, including a notable ranking as the number one medical device company on Fast Company's list of the World's Most Innovative Companies of 2024.
About Cresilon
Cresilon, located in Brooklyn, focuses on developing, manufacturing, and marketing cutting-edge hemostatic medical devices. With a strong commitment to employing its hydrogel technology, the company aims to redefine industry standards in emergency care and surgery. Cresilon is dedicated to advancing medical technologies to enhance patient outcomes and is passionate about making a positive impact within the community. To learn more about Cresilon's pioneering efforts, please visit the official website.
Frequently Asked Questions
What is TRAUMAGEL?
TRAUMAGEL is a hemostatic medical device developed by Cresilon that stops bleeding quickly in emergency situations.
When will Cresilon present its case study?
The case study presentation is scheduled for a Tuesday during the Military Health System Research Symposium.
Where will the MHSRS be held?
The MHSRS will take place at the Gaylord Palms Resort and Convention Center.
What is the focus of the MHSRS?
The MHSRS focuses on military health care unique needs and facilitates research sharing for improved medical care.
How does Cresilon's technology differ?
Cresilon's technology is notable for its effectiveness in stopping bleeding in seconds, using a plant-based hydrogel.
